12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-19), Oncotelic Therapeutics's 12-1 Month Momentum % is -26.75%.
The industry rank for Oncotelic Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
OTLC's 12-1 Month Momentum % is ranked better than 51.76% of 1480
companies
in the Biotechnology industry
Industry Median: -25.2
vs OTLC: -26.75
Competitive Comparison
For the Biotechnology subindustry, Oncotelic Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncotelic Therapeutics 12-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Oncotelic Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Oncotelic Therapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Oncotelic Therapeutics 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Oncotelic Therapeutics's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncotelic Therapeutics (Oncotelic Therapeutics) Business Description
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OTLC has been successfully added to your